ORIC Pharmaceuticals Inc.

5.78
0.25 (4.52%)
At close: Apr 02, 2025, 3:59 PM
5.50
-4.68%
Pre-market: Apr 03, 2025, 04:45 AM EDT
4.52%
Bid 5.03
Market Cap 410.18M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1.83
PE Ratio (ttm) -3.16
Forward PE -5.52
Analyst Buy
Ask 7
Volume 485,812
Avg. Volume (20D) 1,071,978
Open 5.40
Previous Close 5.53
Day's Range 5.41 - 5.98
52-Week Range 5.25 - 14.67
Beta 1.25

About ORIC

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; an...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2020
Employees 115
Stock Exchange NASDAQ
Ticker Symbol ORIC
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 246.32% from the latest price.

Stock Forecasts
1 month ago
+2.72%
Oric Pharmaceuticals shares are trading higher. JP... Unlock content with Pro Subscription
5 months ago
-0.42%
Oric Pharmaceuticals shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a price target of $17.